IXICO Management

Management criteria checks 3/4

IXICO's CEO is Giulio Cerroni, appointed in Feb 2017, has a tenure of 7.17 years. total yearly compensation is £328.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.02% of the company’s shares, worth €46.77K. The average tenure of the management team and the board of directors is 7.2 years and 4.7 years respectively.

Key information

Giulio Cerroni

Chief executive officer

UK£328.0k

Total compensation

CEO salary percentage	100.0%
CEO tenure	7.2yrs
CEO ownership	1.0%
Management average tenure	7.2yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Giulio Cerroni's remuneration changed compared to IXICO's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	UK£328k	UK£328k	-UK£1m
Jun 30 2023	n/a	n/a	-UK£519k
Mar 31 2023	n/a	n/a	UK£139k
Dec 31 2022	n/a	n/a	UK£586k
Sep 30 2022	UK£318k	UK£316k	UK£1m
Jun 30 2022	n/a	n/a	UK£935k
Mar 31 2022	n/a	n/a	UK£838k
Dec 31 2021	n/a	n/a	UK£1m
Sep 30 2021	UK£415k	UK£313k	UK£2m
Jun 30 2021	n/a	n/a	UK£1m
Mar 31 2021	n/a	n/a	UK£1m
Dec 31 2020	n/a	n/a	UK£1m
Sep 30 2020	UK£538k	UK£279k	UK£952k
Jun 30 2020	n/a	n/a	UK£822k
Mar 31 2020	n/a	n/a	UK£692k
Dec 31 2019	n/a	n/a	UK£562k
Sep 30 2019	UK£546k	UK£216k	UK£432k
Jun 30 2019	n/a	n/a	UK£199k
Mar 31 2019	n/a	n/a	-UK£34k
Dec 31 2018	n/a	n/a	-UK£351k
Sep 30 2018	UK£386k	UK£211k	-UK£668k

Compensation vs Market: Giulio's total compensation ($USD412.01K) is about average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Giulio's compensation has increased whilst the company is unprofitable.

CEO

Giulio Cerroni (62 yo)

7.2yrs

Tenure

UK£328,000

Compensation

Mr. Giulio Cerroni has been Chief Executive Officer of IXICO Plc since February 6, 2017 and serves as its Director. Mr. Cerroni has almost 30 years of international management experience gained in life sci...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Giulio Cerroni	CEO & Director	7.2yrs	UK£328.00k	1.02% £ 46.8k
Grant Nash	CFO, Company Secretary & Executive Director	5yrs	UK£216.00k	0.41% £ 19.0k
Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	20.3yrs	no data	no data
Derek Lionel Hill	Co-Founder and President of Regulatory Science & External Relations	6.8yrs	UK£387.01k	no data
David Hawkes	Co-Founder & Member of Scientific Advisory Board	20.3yrs	no data	no data
Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	20.3yrs	no data	no data
Mark Austin	Director of Technology	no data	no data	no data
Robin Wolz	Chief Scientific Officer	no data	no data	no data
Hannah Esfahanian	HR Manager	no data	no data	no data
John Hall	Senior Vice President of Business Development	7.9yrs	no data	no data
Lammert Albers	Chief Business Officer	4.5yrs	no data	no data
Alison Howie	Chief Product Officer	5.8yrs	no data	no data

7.2yrs

Average Tenure

57yo

Average Age

Experienced Management: PYPB's management team is seasoned and experienced (7.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Giulio Cerroni	CEO & Director	7.2yrs	UK£328.00k	1.02% £ 46.8k
Grant Nash	CFO, Company Secretary & Executive Director	4.7yrs	UK£216.00k	0.41% £ 19.0k
Daniel Rueckert	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
David Hawkes	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Joseph Hajnal	Co-Founder & Member of Scientific Advisory Board	no data	no data	no data
Dipti Amin	Independent Non-Executive Director	less than a year	no data	no data
Mark Warne	Independent Non-Executive Chair	7.6yrs	UK£31.00k	0.041% £ 1.9k
Katherine Rogers	Senior Independent Non-Executive Director	2.3yrs	UK£31.00k	no data

4.7yrs

Average Tenure

58yo

Average Age

Experienced Board: PYPB's board of directors are considered experienced (4.7 years average tenure).

IXICO Management

Management criteria checks 3/4

Key information

Recent management updates

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024

IXICO plc, Annual General Meeting, Jan 25, 2024

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

IXICO plc, Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

Recent updates

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Giulio Cerroni to Retire as Director of IXICO plc, Effective End of 2024

Full year 2023 earnings released: UK£0.024 loss per share (vs UK£0.021 profit in FY 2022)

IXICO plc, Annual General Meeting, Jan 25, 2024

IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023

New major risk - Market cap size

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

New major risk - Revenue and earnings growth

IXICO plc Provides Earnings Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.004 profit in 1H 2022)

IXICO plc to Report First Half, 2023 Results on May 23, 2023

IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024

IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024

Full year 2022 earnings released: EPS: UK£0.021 (vs UK£0.033 in FY 2021)

IXICO plc, Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Financial Year 2023

First half 2022 earnings released

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Six Months Ended March 31, 2022

IXICO plc Announces the Launch of IXIQ.Ai, A Novel Platform for Brain Segmentation Based on Convolutional Neural Networks

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS UK£0.018 (vs UK£0.01 in 1H 2020)

Investor sentiment improved over the past week

IXICO plc Provides Earnings Guidance for the Six Months Ended 31 March 2021

IXICO plc announced that it has received £1.2 million in funding from Merchant Capital Manager Limited

Investor sentiment improved over the past week

IXICO plc Announces Collaboration with Microsoft

Ixico plc Announces That It Has Been Selected by A Current Mid-Sized Biopharmaceutical Client to Support the Company's Phase Ii Alzheimer's Disease Clinical Trial

IXICO plc Announces That It Has Been Selects by Cyclerion Therapeutics, Inc

New 90-day low: €0.98

IXICO Secures New Contract for £3.4 Million

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS UK£0.02

Revenue beats expectations

IXICO plc, Annual General Meeting, Jan 21, 2021

IXICO plc Announces £1.9 Million New Study Award

Market bids up stock over the past week

New 90-day high: €1.26

Market bids up stock over the past week

IXICO plc to Report Fiscal Year 2020 Results on Dec 02, 2020

Market bids up stock over the past week

New 90-day high: €1.22

Market bids up stock over the past week

IXICO plc and NYU Langone Health Signs Agreement

IXICO plc Announces £2 Million Contract Extension Win - Huntington’s Disease

Ixico plc Enters into 5 Year Collaboration with Friedreich's Ataxia Research Alliance

Global Alzheimer's Platform Foundation Selects IXICO plc for Innovative Bio-Hermes Trial

New 90-day high - €0.94

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age